11 results for "Anthony Conley"
Showing 1–11 · 0.99 seconds · RSS
-
Journal Article
TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME…
-
Journal Article
Hypothesis: AdAPT-001 and pseudoprogression – when seeing is not necessarily believing
The purpose of this commentary is to highlight the high occurrence of clinical pseudoprogression and delayed responses that have been observed to date with the locally injected oncolytic adenovirus, AdAPT-001, currently in a Phase 1/2 clinical trial (NCT04673942) for the treatment of…
-
Journal Article
The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions
Cellular therapies representa promising area of immunotherapy for advanced cancers,therapies including T cell receptor (TCR) therapies, chimeric antigen receptor (CAR) T cell therapies, tumor-infiltrating lymphocyte (TIL) therapies, and natural killer (NK) cell therapies.Sarcomas pose unique…
-
Journal Article Full text
Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience
Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibrous origin. The 2013 WHO classification of soft tissue tumors defines malignant forms as hypercellular, mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, tumor necrosis, and/or infiltrative margins. With an…
Also available at: DOAJ
-
Journal Article
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Abstract Background Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. Methods…
-
Journal Article
Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma
Summary: Rhabdomyosarcoma accounts for roughly 1% of adult sarcomas, with pleomorphic rhabdomyosarcoma (PRMS) as the most common subtype. Survival outcomes remain poor for patients with PRMS, and little is known about the molecular drivers of this disease. To better characterize PRMS, we performed…
-
Journal Article Full text
Casting a wider net: Immunosurveillance by nonclassical MHC molecules
Most studies of T lymphocytes focus on recognition of classical major histocompatibility complex (MHC) class I or II molecules presenting oligopeptides, yet there are numerous variations and exceptions of biological significance based on recognition of a wide variety of nonclassical MHC molecules…
Also available at: DOAJ
-
Journal Article
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experience
BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common types of soft tissue sarcoma (STS) characterized by liposarcomatous differentiation and a predilection for the retroperitoneum. Despite the growing number of histology-specific immune checkpoint blockade (ICB) trials in STS…